Novo Nordisk, the company behind blockbuster weight-loss drugs like Ozempic and Wegovy, had a deal with Hims & Hers that ...

Novo Nordisk said Monday it will end its collaboration with Hims & Hers that offered the weight loss medication Wegovy for patients who have a prescription for the medication but no insurance coverage ...

The home builder says it has worked to lower its build times and reduce direct construction costs as it navigates softer market conditions. The airline's relisting comes against the backdrop of an ...

Teladoc Health stock price surged by over 14% on Monday, its best single-day gain since April 9. What next for the TDOC share ...

Stock markets have rallied after U.S. President Donald Trump announced a ceasefire in the Israel-Iran conflict, although the ...

Futures data from IG suggests a positive start for European markets, with London's FTSE looking set to open 0.3% higher at ...

The Danish pharmaceutical said it was ending the partnership because Hims is selling and promoting a cheaper copycat of its blockbuster drug Wegovy.

The Danish maker of obesity drugs abruptly ended a Wegovy distribution deal with the telehealth firm, citing allegations ...

First, the stock has sliced through two support levels. Shares broke through their 50-day moving average on Monday for the ...

The pharmaceutical company alleges Hims is widely selling cheaper versions of its blockbuster drugs, despite the FDA's recent ...